<DOC>
	<DOCNO>NCT02737709</DOCNO>
	<brief_summary>By detect blood concentration paclitaxel ( PTX ) , Investigator assume research identify individual difference PTX pharmacokinetics ( PK ) parameter ( TC &gt; 0.05 refers duration paclitaxel plasma concentration 0.05 µmol/L ) Chinese non-small cell lung cancer ( NSCLC ) patient , find correlation PK result PTX toxicities Effectiveness , acquire optimization method PTX , finally try explore individualized PTX pharmacokinetically-guided dosing strategy . Orally administer rosiglitazone , substrate CYP2C8 paclitaxel , chemotherapy injection . Detect blood concentration rosiglitazone , analyze correlation rosiglitazone pharmacokinetic parameter paclitaxel exposure , explore effect rosiglitazone vivo probe paclitaxel exposure . 1 . The variability paclitaxel concentration patient population dose body surface area ( BSA ) , limitation BSA-based dosing paclitaxel . 2 . Verify paclitaxel TC &gt; 0.05 relevant predictor haematological toxicity clinical outcome . 3 . Define dose algorithm base paclitaxel TC &gt; 0.05 paclitaxel quantify effect reduce toxicity improve Effectiveness . 4 . The effect use dose modification administration G-CSF base toxicity determine paclitaxel TC &gt; 0.05 measurement . 5 . Construct trial outline aim reduce grade 4 neutropenia toxicity ensure clinical outcome use individual dose adjustment base dose algorithm . 6 . Detect blood concentration rosiglitazone orally administration , explore effect rosiglitazone vivo probe paclitaxel exposure base CYP2C8 activity . Attempt establish model predict paclitaxel exposure patient base rosiglitazone blood concentration chemotherapy .</brief_summary>
	<brief_title>Paclitaxel Detection NSCLC Treated With TC Regimen</brief_title>
	<detailed_description>Rosiglitazone probe : Rosiglitazone : time point - least 20 hour initiation chemotherapy , orally administrate 2mg rosiglitazone . Only first cycle chemotherapy . Chemotherapy regimen : Paclitaxel : 175mg/m2 , d1 ; Intravenous drip injection 500ml N.S Carboplatin : AUC=5 , d1 ; Intravenous drip injection 500ml G.S Paclitaxel injection first , follow Carboplatin injection . 21 day per cycle ; 6 cycle total . Blood sample collection design : 1 . Rosiglitazone blood sample : Only one blood sample 1st cycle : - Sample collect 3 hour orally administration rosiglitazone , EDTA blood tube , least 4ml ; 2 . Paclitaxel blood sample : Two blood sample per cycle : - Sample collect PTX , EDTA blood tube , least 2ml ; - Sample collect 24 hour initiation PTX , EDTA blood tube , least 2ml ; Primary Objective : Object response rate ( ORR ) : ass ORR paclitaxel/carboplatin chemotherapy accord Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 , analyze relationship paclitaxel TC &gt; 0.05 ORR . Secondary Objectives : Pharmacokinetic parameter : detect blood concentration paclitaxel 24 hour initiation , blood concentration rosiglitazone 3 hour orally administration rosiglitazone . Calculate paclitaxel TC &gt; 0.05 analyze correlation rosiglitazone concentration paclitaxel TC &gt; 0.05 . Toxicities rate : assess toxicity rate severity paclitaxel/carboplatin chemotherapy accord Common Terminology Criteria For Adverse Events ( CTCAE ) v4.03 , analyze relationship paclitaxel TC &gt; 0.05 toxicity . Survival Effectiveness : assess progression free survival ( PFS ) overall survival ( OS ) paclitaxel/carboplatin chemotherapy , analyze relationship paclitaxel TC &gt; 0.05 survival Effectiveness . A single arm , phase II , monocentric , clinical experience trial . The eligible patient sign inform consent form , receive 4 - 6 cycle paclitaxel/carboplatin chemotherapy . Objective response rate evaluate image examination ( CT MR scan ) every 2 cycle . Toxicities evaluate patient ' diary toxicity report physician 's evaluation day 10 day 21 every cycle . Blood sample collect every cycle . And survival information collect clinic telephone follow-up . Response follow-up : An image examination perform 4weeks treatment initiation , patient go receive ( CT MR scan ) every 2 cycle treatment , method identical baseline . Toxicities follow-up : record toxicities incident grade first cycle last cycle toxicity relieve stabilize . Survival follow-up : treatment discontinuation , PFS record image examination every 2 cycle ( 8 week ) tumor progression , anti-cancer treatment start , trial end death . OS record clinic follow-up telephone follow-up death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age : 18 ~75 year Pathology : Confirmed pathology ( histology cytology ) advance nonsmall cell lung cancer Have indication paclitaxel/carboplatin chemotherapy , suitable paclitaxel chemotherapy ( independent clinical tumor stage chemotherapy type palliative chemotherapy line ) At least one measurable tumor lesion ( accord RECIST 1.1 criterion ) ECOG PS score : 0 2 point Life expectancy : 3 month Bone marrow reserve function good , function organ ( liver kidney ) good , satisfy condition implementation chemotherapy . neutrophil count ≥1.5×109/l , platelet ≥75×109/l , hemoglobin &gt; 9g/dl , Total Bilirubin ≤1.5×ULN* , transaminase &lt; 2.5×ULN* , creatinine ≤1.5×ULN* , creatinine clearance rate ≥45ml/min . ULR : Upper Limit Of Normal . Sign inform consent form ; Compliance good , follow , willing comply requirement study ECOG Performance Scores &gt; 2 point Organic disease ( heart , liver , kidney disease etc ) , Active infection Organ transplantation immunosuppressive therapy , capable complete 4 6 cycle paclitaxel / carboplatin chemotherapy . Any tumor history cure 3 year trial . Bone marrow function organ function eligible chemotherapy . Diabetic patient currently receive standard anti diabetes treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>